Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

ose in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Jennifer Anderson

(800) 987-8256 (212) 918-4642


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... Research Triangle Park, NC (PRWEB) January 14, 2014 ... diagnostic company focusing on ultra-sensitive POC diagnostic platforms and novel ... on their first round of financing netting a total of ... first outside equity capital in the company. This group of ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... 29 Reportlinker.com announces that a ... in its catalogue. , ... Broadening Market , ... diagnostic applications in the areas of ...
... Zealand, Oct. 29 ZyGEM Corp. Ltd., a provider ... life sciences applications, today announced it has entered into ... DNA extraction products to the Japanese market. This ... recent major distribution agreements for ZyGEM,s DNA extraction kits ...
... 29 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management ... Thursday, October 29 at 10:00 a.m. Pacific Time. , The conference is being ... presentation will be webcast live with slides and available for replay afterwards. The ... ...
Cached Biology Technology:Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 2Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 3Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 4Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 5Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 6ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 2ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 3ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 4
(Date:4/18/2014)... researchers have published soil organic carbon sequestration rates. ... organic carbon can be sequestered by simply switching from ... there is a growing body of research with evidence ... cover crops, small grains, and forages may not be ... , "Some studies have shown that both moldboard and ...
(Date:4/17/2014)... April 17 In the most densely forested and ... reflect two centuries of human needs, values and practices. ... clearing forests for agriculture and development, have set the ... U.S. Forest Service study reports. , The report ... and management needs in the Northern United States ...
(Date:4/17/2014)... West Orange, NJ. April 16, 2014. Kessler Foundation ... for $1.8 million from the Department of Defense ... PhD, is principal investigator for the randomized, double-blinded, ... to improve bone and muscle strength after spinal ... Human Performance & Engineering Research at Kessler Foundation. ...
Breaking Biology News(10 mins):Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... more about a tumor,s underlying biology, personalized medicine ... This year, the American Association for ... in Cancer Therapeutic Development: Challenges and Horizons conference ... Colo. This meeting regularly draws representatives from academia ...
... Pancreatic cancers use the sugar fructose, very common in ... drives cell division, helping the cancer to grow more quickly, ... has found. Although it,s widely known that cancers use ... the first time a link has been shown between fructose ...
... August 3rd, as part of the Ecological Society ... of scientists will discuss the environmental impacts of ... some of the most diverse habitats on the ... altered by mountaintop removal and valley fill mining. ...
Cached Biology News:Pancreatic cancers use fructose, common in the Western diet, to fuel their growth 2Pancreatic cancers use fructose, common in the Western diet, to fuel their growth 3Ecologists to discuss impacts of mountaintop mining at special ESA symposium 2Ecologists to discuss impacts of mountaintop mining at special ESA symposium 3
... Probes EnzChek Pyrophosphate Detection Kit,provides a ... measuring the inorganic pyrophosphate (PPi ) ... such as DNA and,RNA polymerizations, cyclic ... and the enzymatic activation of fatty ...
... is an intracellular marker normally present at ... subpopulation of bone marrow prelymphocytes. Elevated levels ... TdT cells are found to be associated ... of TdT thus provides a useful adjunct ...
... NOT FREEZE. Nuclear matrix proteins (NMPs) make up ... are associated with such functions as DNA replication, ... nuclear matrix has been shown to be highly ... known that cell death releases soluble nuclear matrix ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
Biology Products: